Genprex

Category: Press Releases

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

Read More

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

Read More

Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genprex announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.

Read More

Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at NobleCon16 Investor Conference

Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.

Read More

Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy

The study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to the growing body of research on TUSC2 beyond the non-small lung cell cancer indication the Company is initially pursuing

Read More

Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso®

Read More

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

Genprex today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.

Read More

Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

Genprex announced that the FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.

Read More